Foody J M, Nissen S E
Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8025, USA.
Am J Cardiol. 2001 Aug 16;88(4A):31F-5F. doi: 10.1016/s0002-9149(01)01875-6.
Over the past several years, results of clinical trials of lipid lowering have increased our understanding of the pathophysiology of coronary atherosclerosis and ischemia. Evidence is accumulating that cholesterol lowering has potential anti-ischemic effects and may have immediate consequences that have a favorable impact on coronary events, possibly even acute coronary syndromes. Yet, less than one half of all patients hospitalized for acute coronary syndromes have their cardiovascular risks appropriately modified. The results of recent statin trials provide impetus for the implementation of aggressive risk-reduction strategies in patients with coronary atherosclerosis, including those with recent acute coronary syndromes. Prevention is now a viable therapeutic goal.
在过去几年中，降脂临床试验的结果增进了我们对冠状动脉粥样硬化和缺血病理生理学的理解。越来越多的证据表明，降低胆固醇具有潜在的抗缺血作用，可能会对冠状动脉事件甚至急性冠状动脉综合征产生有利影响的直接后果。然而，因急性冠状动脉综合征住院的患者中，不到一半的人心血管风险得到了适当改善。近期他汀类药物试验的结果为对冠状动脉粥样硬化患者（包括近期发生急性冠状动脉综合征的患者）实施积极的风险降低策略提供了动力。预防现在是一个可行的治疗目标。
